• Product name
    Anti-P Glycoprotein antibody [F4]
    See all P Glycoprotein primary antibodies
  • Description
    Mouse monoclonal [F4] to P Glycoprotein
  • Specificity
    ab80594 detects soluble P glycoprotein in the cultured media of viable adriamycin-resistant cells, whereas those of the drug-sensitive parent cells contain no detectable level of soluble P glycoprotein. We have data to indicate that this antibody may not cross react with Mouse. However, this has not been conclusively tested and expression levels may vary in certain cell lines/tissues.
  • Tested applications
    Suitable for: IHC-P, WB, Flow Cyt, ICC/IFmore details
  • Species reactivity
    Reacts with: Human, Chinese hamster
  • Immunogen

    Human and hamster drug-resistant viable cells followed by crude plasma membranes.

  • Epitope
    Extracellular amino terminal half. This epitope is resistant to formalin fixation and periodate oxidation.
  • Positive control
    • Drug resistant cells. Human kidney or breast carcinoma.
  • General notes

    Abcam is committed to meeting high standards of ethical manufacturing and has decided to discontinue this product by June 2019 as it has been generated by the ascites method. We are sorry for any inconvenience this may cause. We would recommend antibody ab170904 as a replacement.



Our Abpromise guarantee covers the use of ab80594 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt
  • Application notes
    Flow Cyt: Use at an assay dependent dilution.
    ICC/IF: Use at an assay dependent dilution.
    IHC-P: Use at an assay dependent dilution.
    WB: Use at a concentration of 1 - 2 µg/ml. Predicted molecular weight: 141 kDa.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
    • Tissue specificity
      Expressed in liver, kidney, small intestine and brain.
    • Involvement in disease
      Genetic variations in ABCB1 are associated with susceptibility to inflammatory bowel disease type 13 (IBD13) [MIM:612244]. Inflammatory bowel disease is characterized by a chronic relapsing intestinal inflammation. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may involve any part of the gastrointestinal tract, but most frequently the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Crohn disease and ulcerative colitis are commonly classified as autoimmune diseases.
    • Sequence similarities
      Belongs to the ABC transporter superfamily. ABCB family. Multidrug resistance exporter (TC 3.A.1.201) subfamily.
      Contains 2 ABC transmembrane type-1 domains.
      Contains 2 ABC transporter domains.
    • Cellular localization
    • Information by UniProt
    • Database links
    • Alternative names
      • ABC20 antibody
      • ABCB1 antibody
      • ATP binding cassette, sub family B (MDR/TAP), member 1 antibody
      • ATP-binding cassette sub-family B member 1 antibody
      • CD243 antibody
      • CLCS antibody
      • Colchicin sensitivity antibody
      • Doxorubicin resistance antibody
      • GP170 antibody
      • MDR1 antibody
      • MDR1_HUMAN antibody
      • Multidrug resistance 1 antibody
      • Multidrug resistance protein 1 antibody
      • P glycoprotein 1 antibody
      • P gp antibody
      • P-glycoprotein 1 antibody
      • PGY1 antibody
      see all


    This product has been referenced in:
    • Mesgari Abbasi M  et al. The Effects of Cetirizine on P-glycoprotein Expression and Function In vitro and In situ. Adv Pharm Bull 6:111-8 (2016). Read more (PubMed: 27123426) »
    • Ganta S  et al. Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer. Drug Deliv 23:968-80 (2016). Read more (PubMed: 24901206) »

    See all 6 Publications for this product

    Customer reviews and Q&As

    Thank you for contacting us.

    Below is a link to our thorough western blot guide, which includes tips on sample preparation, running, and transfering large proteins.


    For yo...

    Read More

    I can confirm that it should not be necessary to prepare a membrane fraction in order to detect this protein.

    In case you are experiencing high background or to enrich the protein when low signal occurs, I would recommend preparing ...

    Read More

    Thank you for passing on that reply.

    I am sorry to hear that the customer has still not observed the expected signal with the anti-P Glycoprotein antibody (ab3366).

    As I mentioned in my previous email, I would be happy to provide the ...

    Read More

    Thank you for your enquiry.

    I can confirm that the epitope of ab80594 Anti-P Glycoprotein antibody [F4] is within the extracellular amino terminal end of the protein.

    I hope this will be helpful. If you have any further questions,...

    Read More

    Thank you for your enquiry and your interest in our products.

    Here are a few antibodies against the following targets which have been tested and characterized for Flow cytometry. Please take a look at the on-line datasheets for further inform...

    Read More

    Thank you for contacting us. ab3364; anti P Glycoprotein is no longer available in our catalogue. However we have similar products available to buy. The catalogue numbers are ab3083; ab3366; ab10333; ab80594; ab80626. Please check the da...

    Read More


    Sign up